San Francisco, CA – [Insert Date] – Mirum Pharmaceuticals is accelerating towards a pivotal regulatory submission for its investigational therapy, brelovitug, a promising treatment for chronic Hepatitis Delta Virus (HDV) infection. The company announced a significant positive outcome from its Phase IIb/III AZURE-1 trial, a critical step that propels brelovitug closer to potentially addressing a substantial unmet medical need in a disease characterized by severe liver damage and limited therapeutic options. Mirum anticipates submitting a Biologics License Application (BLA) for brelovitug in the first half of 2027, signaling a new era of hope for patients battling this aggressive form of viral hepatitis.
n
The AZURE-1 trial, a meticulously designed study involving treatment-naïve patients with chronic HDV, has provided compelling evidence of brelovitug’s efficacy and tolerability. The encouraging results from this late-stage investigation, coupled with ongoing research, position Mirum to potentially offer a much-needed therapeutic advancement to a patient population that has historically faced limited treatment avenues.
n
Key Facts at a Glance:
n
- n
- Drug: Brelovitug (Mirum Pharmaceuticals)
- Indication: Chronic Hepatitis Delta Virus (HDV) Infection
- Trial: AZURE-1 (Phase IIb/III)
- Primary Endpoint Achievement: Significant rates of virologic response and alanine transaminase (ALT) normalization at 24 weeks.
- Durability: Sustained viral suppression and increased ALT normalization observed at 48 weeks.
- Safety Profile: Well-tolerated, with injection site reactions as the most common adverse event and no serious adverse events reported in treated individuals at 24 weeks.
- Regulatory Milestone: Planned BLA submission for brelovitug in the first half of 2027.
- Market Potential: Brelovitug aims to enter a market currently led by Gilead Sciences’ Hepcludex (bulevirtide-gmod), approved in May 2026.
n
n
n
n
n
n
n
n
n
Chronology of Development: From Trial Design to Regulatory Horizon
n
The journey of brelovitug towards potential market approval is marked by a strategic and phased clinical development program. The AZURE-1 trial represents a crucial milestone in this progression, building upon earlier research and paving the way for future regulatory actions.
n
Phase IIb/III AZURE-1 Trial Design and Execution:
n
The AZURE-1 trial enrolled treatment-naïve patients diagnosed with chronic HDV infection. The study employed a randomized, controlled design, meticulously evaluating different dosing regimens of brelovitug. Participants were allocated to one of three arms:
n
- n
- Arm 1: Weekly administration of 300mg of brelovitug.
- Arm 2: Weekly administration of 900mg of brelovitug.
- Arm 3: A 24-week treatment delay followed by a 300mg weekly course of brelovitug. This arm served as a control group to assess the natural progression of the disease and the impact of delayed treatment.
n
n
n
n
The primary objective of AZURE-1 was to assess the efficacy of brelovitug in achieving two key indicators of treatment success: virologic response and the normalization of alanine transaminase (ALT) levels. Virologic response was defined as a significant reduction in HDV RNA levels, either by 2 log10 or more from baseline, or achieving undetectable levels of HDV RNA. ALT is an enzyme that leaks into the bloodstream when liver cells are damaged, and its normalization is a strong indicator of reduced liver inflammation and improved liver health.
n
Interim and Long-Term Data Analysis:
n
The trial provided critical data at multiple time points, allowing for a comprehensive evaluation of brelovitug’s impact.
n
- n
- n
24-Week Primary Endpoint Analysis: At the 24-week mark, the results were highly encouraging. In the group receiving 300mg of brelovitug, 56% of patients achieved both a virologic response and normalization of ALT levels. Similarly, 45% of patients in the 900mg arm met these primary endpoints. These figures significantly surpassed expectations and met the trial’s primary objective, demonstrating brelovitug’s potent effect on viral load and liver inflammation.
n
-
48-Week Durability Data: The Phase IIb portion of the AZURE-1 trial extended to 48 weeks, providing valuable insights into the durability of brelovitug’s impact. The data revealed a deepening of viral suppression over time, with an increasing proportion of patients maintaining undetectable HDV RNA levels. Furthermore, the rates of ALT normalization continued to rise, underscoring the sustained therapeutic benefit of brelovitug. This long-term efficacy is crucial for a chronic disease like HDV, where sustained control is essential to prevent further liver damage and complications.
n
Safety and Tolerability:
A paramount consideration in any therapeutic development is patient safety. The AZURE-1 trial demonstrated that brelovitug is generally well-tolerated. The most frequently reported side effect was injection site reactions, a common occurrence with injectable medications. Importantly, at the 24-week assessment, no treated individuals experienced a serious adverse event directly attributable to the study drug. This favorable safety profile was maintained through the 48-week mark, with no new safety concerns emerging. This reassuring safety data is critical for a therapy intended for chronic administration in patients who may already be burdened by liver disease.
Upcoming Milestones and Future Outlook:
The successful completion of AZURE-1 is a catalyst for Mirum’s strategic planning. The company is now eagerly awaiting data from its second late-stage study, AZURE-4 (NCT07298330), also investigating brelovitug in chronic HDV. This pivotal trial is anticipated to provide its readout in the final quarter of 2026.
The combined data from AZURE-1 and AZURE-4 are expected to form the cornerstone of Mirum’s US Biologics License Application (BLA). The company has set an ambitious target, aiming to submit this critical regulatory filing in the first half of 2027. This timeline reflects Mirum’s commitment to expediting the availability of brelovitug to patients.
Should regulatory approvals be granted, Mirum is projecting a market launch for brelovitug in the fourth quarter of 2027. This timeline places brelovitug in a competitive landscape, as Gilead Sciences’ Hepcludex (bulevirtide-gmod) received US regulatory approval for chronic HDV in May 2026, becoming the first drug to achieve this milestone for the indication.
Supporting Data: Unpacking the Efficacy and Safety Findings
The robust data generated from the AZURE-1 trial provides a detailed picture of brelovitug’s therapeutic potential. The study’s design, incorporating multiple endpoints and extended follow-up, allows for a nuanced understanding of its benefits.
Virologic Response and ALT Normalization – The Primary Endpoints:
The achievement of the primary endpoints at 24 weeks is a significant indicator of brelovitug’s effectiveness. The rates of 56% (300mg arm) and 45% (900mg arm) for achieving both virologic response and ALT normalization highlight the drug’s ability to not only suppress the virus but also to ameliorate the underlying liver inflammation. This dual action is crucial for managing chronic HDV, a disease that can rapidly progress to fibrosis, cirrhosis, and hepatocellular carcinoma.
The definition of virologic response, requiring a substantial reduction in HDV RNA or undetectable levels, signifies a meaningful viral clearance. Coupled with ALT normalization, which indicates a return to healthier liver function, these endpoints collectively paint a compelling picture of clinical benefit.
Sustained Viral Suppression and Continued ALT Improvement:
The 48-week data from the AZURE-1 trial offers a critical perspective on the long-term impact of brelovitug. The observation that viral suppression rates deepened and ALT normalization rates increased over time suggests that brelovitug may offer sustained control of the disease. This sustained efficacy is a vital characteristic for any treatment aimed at managing a chronic viral infection, as intermittent or waning responses can lead to disease progression and suboptimal outcomes. The ability of brelovitug to maintain and potentially improve its therapeutic effect over an extended period is a significant advantage.
A Favorable Safety Profile for Chronic Treatment:
The safety and tolerability data from AZURE-1 are highly encouraging, particularly for a therapy intended for chronic use. The identification of injection site reactions as the most common adverse event is a manageable concern. The absence of serious adverse events directly attributed to brelovitug at 24 weeks, and the lack of new safety signals through 48 weeks, strongly support the drug’s potential for long-term patient use. A well-tolerated drug profile is essential for ensuring patient adherence and improving overall quality of life, especially for individuals managing a chronic illness.
Official Responses and Expert Opinions
The positive results from the AZURE-1 trial have elicited enthusiastic responses from Mirum Pharmaceuticals leadership and key investigators, underscoring the significance of these findings for the HDV community.
Mirum Pharmaceuticals’ Perspective:
Nancy Shulman, EVP of Clinical Development at Mirum Pharmaceuticals, expressed optimism about the trial’s outcomes. "We are extremely encouraged by the late-stage clinical evidence demonstrating that brelovitug is a well-tolerated, convenient, single agent that can deliver deepening responses over time," Shulman stated. She further emphasized the broad applicability of these findings: "Notably, these results were achieved in a broad patient population, including those with significant liver inflammation, cirrhosis, and clinically significant portal hypertension." This highlights brelovitug’s potential to benefit a wide spectrum of HDV patients, including those with more advanced disease.
Investigator Insights:
Dr. Norah Terrault, a leading investigator for the AZURE-1 trial and Chief of the GI and Liver Division at USC’s Keck School of Medicine, provided a crucial clinical perspective. She noted that brelovitug’s demonstration of a combination of virologic response and ALT normalization is an "encouraging signal for a long term therapy." Dr. Terrault further commented that these results represent "an important step forward for patients with HDV," acknowledging the significant unmet need in this disease area. Her endorsement from a prominent figure in hepatology lends considerable weight to the trial’s findings.
Implications for the HDV Treatment Landscape
The promising data from Mirum’s AZURE-1 trial carries significant implications for the future of chronic HDV management.
Addressing a Critical Unmet Need:
Chronic HDV infection is one of the most severe forms of viral hepatitis, characterized by rapid progression to cirrhosis, liver failure, and hepatocellular carcinoma. For decades, treatment options have been extremely limited, with interferon-based therapies offering modest efficacy and significant side effects. The advent of brelovitug, if approved, represents a significant therapeutic advancement, offering the potential for more effective viral suppression and liver health improvement.
The Competitive Landscape:
Mirum’s brelovitug is poised to enter a market that has recently seen its first entrant. Gilead Sciences’ Hepcludex (bulevirtide-gmod) was approved by the FDA in May 2026, marking a landmark moment for HDV patients. Hepcludex, a first-in-class inhibitor of the sodium taurocholate cotransporting polypeptide (NTCP) transporter, targets the initial entry of HBV and HDV into hepatocytes.
The emergence of brelovitug, a potentially distinct mechanism of action, suggests a future with multiple therapeutic options for HDV. This competition is ultimately beneficial for patients, driving innovation and potentially leading to more personalized treatment approaches. Analysts at GlobalData, the parent company of Clinical Trials Arena, had previously recognized Hepcludex’s approval as a "significant milestone" for patients. The introduction of brelovitug will further build upon this progress.
Potential for Improved Patient Outcomes:
The combination of potent viral suppression and normalization of liver enzymes, as demonstrated by brelovitug, holds the promise of significantly altering the natural history of chronic HDV. By controlling viral replication and reducing liver inflammation, brelovitug could potentially prevent or delay the onset of severe liver complications such as cirrhosis and liver cancer. Furthermore, the reported favorable safety profile and convenience of administration (weekly injection) could lead to improved patient adherence and quality of life compared to older treatment regimens.
Future Research and Development:
The success of brelovitug will likely spur further research into HDV pathogenesis and the development of novel therapeutic strategies. The insights gained from brelovitug’s mechanism of action and clinical performance may inform the design of future drug candidates and combination therapies. The ongoing focus on HDV by pharmaceutical companies like Mirum signifies a growing commitment to addressing this neglected disease, offering renewed hope for millions worldwide affected by chronic HDV infection. The company’s proactive approach to regulatory submissions and market entry demonstrates a clear vision to bring this potentially life-changing therapy to patients as swiftly as possible.
